Acute-On-Chronic Liver Failure Clinical Trial
— TRUSTOfficial title:
A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure
Verified date | March 2021 |
Source | Martin Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.
Status | Suspended |
Enrollment | 30 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age 18 to 75 years, inclusive, at screening. 2. Stable diagnosis of AD, ACLF Grade 1 or ACLF Grade 2 for no less than 2 days (as determined at the discretion of the investigator)*. 3. Anticipated duration of hospital stay of at least 7 days. 4. For Group 1: - AD with SCr = 1 and < 2 mg/dL, OR - ACLF 1 with - Tbil = 12 mg/dL, SCr = 1.5 and < 2 mg/dl, and HE 0-2, or - Tbil = 12 mg/dL, and SCr < 1.5 mg/dL, and HE 1-2, or - INR = 2.5, SCr = 1.5 and < 2 mg/dl, and HE 0-2, or - INR = 2.5, SCr < 1.5 mg/dL, and HE 1-2, OR - ACLF 2 with - Tbil = 12 mg/dL, INR = 2.5, and SCr < 2 mg/dL, or - Tbil = 12 mg/dL, HE 3-4, and SCr < 2 mg/dL 5. For Group 2: - ACLF 1 with SCr = 2.0 and < 3.5 mg/dL, OR - ACLF 2 with - Tbil = 12 mg/dL, and SCr = 2 and < 3.5 mg/dL, or - INR = 2.5, and SCr = 2 and < 3.5 mg/dL. 6. Female patients must be of non-childbearing potential, or, if non-sterile, must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose. 7. Non sterile male patients must agree to sexual abstinence or use a highly effective method of contraception from Screening to 3 days after the final dose if sexually active. 8. Able to comprehend and willing to sign an informed consent form, or, if unable to consent, consent is conducted per local requirements. Exclusion Criteria: 1. Diagnosis of AD or ACLF (of any grade) >14 days before enrollment*. 2. Circulatory failure. 3. Respiratory failure i.e. PaO2/FiO2 = 200 and/or baseline SpO2/FiO2 = 214. 4. Brain failure (West Haven grade 3 or 4 hepatic encephalopathy) with coagulation failure (INR > 2.5). 5. Gastrointestinal bleeding within 72 hours prior to enrollment. (Subjects who fail this criterion may qualify after 72 hours). 6. Uncontrolled bacterial infection (urinary tract infection, spontaneous bacterial peritonitis, pneumonia, bacteremia, soft tissue infections, etc.) (as determined at the discretion of the investigator). 7. Invasive fungal infection. 8. Platelet count <30,000 cells/mL. 9. White blood cell count <1000 cells/uL. 10. Patients on hemodialysis or continuous venovenous hemofiltration. 11. Patients who have undergone or are scheduled for imminent organ transplantation. (Patients may be on a transplant list as long as no date has been set for transplantation) 12. Hospitalization for ACLF within the 3 months prior to screening. 13. History of hepatocellular carcinoma, unless within Milan Criteria (up to 3 lesions each < 3 cm or 1 lesion < 5 cm; no extrahepatic involvement; no evidence of gross vascular invasion). 14. Active non-hepatic malignancy. 15. Parkinson's disease, Parkinsonian-type symptoms (gait disorder, tremor, etc.), restless leg syndrome or other movement disorders other than asterixis. 16. Fulminant Wilson's, fulminant autoimmune hepatitis, or Budd-Chiari syndrome. 17. Septic shock (hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (> 18 mg/dL) after adequate fluid resuscitation. 18. Patients who have undergone placement of a transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt in the past 6 months. 19. Any invasive procedure within 48 hours prior to enrollment with high risk of uncontrolled bleeding (as determined at the discretion of the investigator). 20. Female with a positive pregnancy test or lactating. 21. Positive results for human immunodeficiency virus HIV-1 or HIV-2. 22. Current treatment with trimetazidine. 23. Known allergy to trimetazidine or excipients. 24. Currently receiving an investigational treatment. 25. Any condition that, in the opinion of the Investigator (or designee), would limit the subject's ability to complete or participate in this clinical study. |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Graz | Graz | |
Austria | Medical University of Innsbruck | Innsbruck | |
Austria | Medical University of Vienna | Vienna | |
Belgium | University of Antwerp | Antwerp | |
Belgium | Erasme Hospital | Brussels | |
France | Hospital Claude Huriez | Lille | |
France | Hospital Pitie-Salpetriere | Paris | |
France | Rennes University Hospital | Rennes | |
France | Hôpital Paul Brousse | Villejuif | |
Germany | University of Essen | Essen | |
Germany | JW Goethe Clinic | Frankfurt | |
Germany | Universitätsklinikum Halle Klinik und Poliklinik für Innere Medizin I | Halle | |
Germany | University of Hannover | Hannover | |
Germany | University of Heidelberg | Heidelberg | |
Germany | University of Leipzig | Leipzig | |
Germany | University of Münster | Münster | |
Spain | Hospital Clinic | Barcelona | |
Spain | Hospital Valle de Hebron | Barcelona | |
Spain | Hospital Reina Sofia | Córdoba | |
Spain | Hospital Gregorio Marañón | Madrid | |
Spain | Hospital Puerta de Hierro | Madrid | |
Spain | Hospital Ramon y Cajal | Madrid | |
Spain | Hospital Marques de Valdecilla Santander | Santander | |
Spain | Hospital Virgen del Rocio | Seville |
Lead Sponsor | Collaborator |
---|---|
Martin Pharmaceuticals |
Austria, Belgium, France, Germany, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | plasma pharmacokinetics | Cmax | 28 days | |
Primary | plasma pharmacokinetics | AUC | 28 days | |
Secondary | Incidence of treatment-emergent adverse events [Safety and Tolerability] | Adverse events | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05985863 -
Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04822922 -
Safety of UC-MSC Transfusion for ACLF Patients
|
Phase 2 | |
Recruiting |
NCT04578301 -
Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
|
||
Completed |
NCT04983108 -
Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure
|
||
Withdrawn |
NCT05940610 -
The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05036031 -
Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
|
||
Recruiting |
NCT05019352 -
Cytokine Adsorption in Acute-on-chronic Liver Failure
|
N/A | |
Recruiting |
NCT05421351 -
Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
|
||
Completed |
NCT02321371 -
Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.
|
N/A | |
Not yet recruiting |
NCT06069037 -
SALT for Treatment of Patients With Early ACLF
|
N/A | |
Completed |
NCT02965560 -
Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
|
||
Recruiting |
NCT03713489 -
Platelet Transfusion in HBV-related acute-on Chronic Liver Failure
|
N/A | |
Withdrawn |
NCT03629015 -
Safety Study of Stemchymal® in Acute Liver Failure
|
Phase 1 | |
Recruiting |
NCT04621812 -
Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
|
||
Recruiting |
NCT04157465 -
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
|
N/A | |
Recruiting |
NCT06128421 -
Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk
|
N/A | |
Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
Completed |
NCT04238416 -
Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF
|
Phase 1 | |
Completed |
NCT03456518 -
Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease
|
||
Recruiting |
NCT03987893 -
PEG3350 in ACLF With Hepatic Encephalopathy
|
Phase 4 |